Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 19 min ago
Peer-reviewedCC BY-NC-NDLancet regional health. Americas

Collaborative intelligence for sustainable and patient-partnered clinical research.

3 more authors
13 affiliations
  1. 1CURA Project Institute, São Paulo, Brazil.
  2. 2AW Scientific Engineering, Londrina, Brazil.
  3. 3Ethics Committee, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
  4. 4Institute D'Or for Research and Education, Rede DOR, Rio de Janeiro, Brazil.
  5. 5Albert Einstein Israelite Hospital (HIAE), São Paulo, Brazil.
  6. 6Daiichi Sankyo, São Paulo, Brazil.
  7. 7Turi Saúde, São Paulo, Brazil.
  8. 8Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.
  9. 9Brazilian Hospital Services Network (EBSERH), Brasília, Brazil.
  10. 10Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
  11. 11Oncoclínicas Group, São Paulo, Brazil.
  12. 12Brazilian Society for Clinical Oncology (SBOC) (XXVI Congress Chair), Rio de Janeiro, Brazil.
  13. 13University Center of Volta Redonda (UNIFOA), Volta Redonda, Brazil.

Abstract

This strategic perspective proposes a governance-oriented conceptual model for sustainable, patient-partnered oncology research in Brazil, with regional relevance for Latin America and broader global implications. It argues that strengthening clinical research ecosystems, currently largely driven by the pharmaceutical industry, requires a refined balance of alignment among sponsors, investigators, institutions, regulators, and patients, recognizing that each operates under distinct strategic, operational, and ethical imperatives. The proposed framework emphasizes equity, meaningful clinical outcomes, and real-world relevance. It is presented as a governance heuristic inspired by strategic interdependence, recognizing that sustainable research ecosystems emerge from coordinated decisions among stakeholders with distinct incentives and responsibilities. A central architectural element is the positioning of patient organizations as institutional integrators of collaborative intelligence across stakeholders. This positioning supports Brazil as a strategic player in globally relevant oncology evidence, strengthening external validity and contributing to the evolution of international standards.

Related

  1. Where did it go? How Information Management Practices Impact Rigor and Reproducibility in Collaborative Clinical and Translational Research
    S. Venkatesh, B. Rolland
    medRxivPreprintAll rights reservedFull textEpidemiology & public healthmedRxivPMC
  2. Immersion 360, a european patient-partnered research project aimed at developing communication skills in paediatrics and raising awareness of interprofessional collaboration practice in partnership.
    Luigi Flora
    HALPreprintCC BY 4.0Full textEcologyEpidemiology & public healthHALHAL
  3. Building sustainable IBD clinical research units: a practical toolbox emerging from a Belgian multi-stakeholder initiative.
    Ingrid Arijs, Leonie Govaerts, Lynn Debrun +10
    Journal of Crohn's & colitisPeer-reviewedCC BY-NCFull textEpidemiology & public healthEurope PMC
  4. Bridging the Translational Gap in Artificial Intelligence for Otology and Neurotology: Clinical Readiness, Limitations, and Research Priorities
    Pasquale Viola, Teodoro Aragona, Pietro De Luca +6
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Fragmented and Underutilized: Exploring Role Variation and Ambiguity for Research Project Managers in Collaborative Team Science
    Shayla A Vradenburgh, Betsy Rolland
    medRxivPreprintAll rights reservedFull textEpidemiology & public healthmedRxivPMC
BibTeX
@article{arai2026collaborative,
  title = {{Collaborative intelligence for sustainable and patient-partnered clinical research.}},
  author = {Roberto J Arai and Fernanda Schwyter and Luciana P Pereira and Clarissa Baldotto and Vanessa Teich and Gabriela Prior and Thiago Liguori and Christopher Booth and Felipe Roitberg and Max S Mano and Carlos E Barrios and William N William and Bernardo Caetano Novaes and Nataline Freitas de Azevedo Santos and Heloisa M Resende},
  journal = {Lancet regional health. Americas},
  year = {2026},
  month = oct,
  doi = {10.1016/j.lana.2026.101679},
  url = {https://europepmc.org/article/MED/42926955},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Collaborative intelligence for sustainable and patient-partnered clinical research.
AU  - Roberto J Arai
AU  - Fernanda Schwyter
AU  - Luciana P Pereira
AU  - Clarissa Baldotto
AU  - Vanessa Teich
AU  - Gabriela Prior
AU  - Thiago Liguori
AU  - Christopher Booth
AU  - Felipe Roitberg
AU  - Max S Mano
AU  - Carlos E Barrios
AU  - William N William
AU  - Bernardo Caetano Novaes
AU  - Nataline Freitas de Azevedo Santos
AU  - Heloisa M Resende
PY  - 2026
DA  - 2026/10/19
JO  - Lancet regional health. Americas
DO  - 10.1016/j.lana.2026.101679
UR  - https://europepmc.org/article/MED/42926955
AB  - This strategic perspective proposes a governance-oriented conceptual model for sustainable, patient-partnered oncology research in Brazil, with regional relevance for Latin America and broader global implications. It argues that strengthening clinical research ecosystems, currently largely driven by the pharmaceutical industry, requires a refined balance of alignment among sponsors, investigators, institutions, regulators, and patients, recognizing that each operates under distinct strategic, operational, and ethical imperatives. The proposed framework emphasizes equity, meaningful clinical outcomes, and real-world relevance. It is presented as a governance heuristic inspired by strategic interdependence, recognizing that sustainable research ecosystems emerge from coordinated decisions among stakeholders with distinct incentives and responsibilities. A central architectural element is the positioning of patient organizations as institutional integrators of collaborative intelligence across stakeholders. This positioning supports Brazil as a strategic player in globally relevant oncology evidence, strengthening external validity and contributing to the evolution of international standards.
SN  - 2667-193X
ER  -